155 related articles for article (PubMed ID: 37334382)
1. Exploration of T cell immune responses by expression of a dominant-negative SHP1 and SHP2.
Taylor J; Bulek A; Gannon I; Robson M; Kokalaki E; Grothier T; McKenzie C; El-Kholy M; Stavrou M; Traynor-White C; Lim WC; Panagiotou P; Srivastava S; Baldan V; Sillibourne J; Ferrari M; Pule M; Thomas S
Front Immunol; 2023; 14():1119350. PubMed ID: 37334382
[TBL] [Abstract][Full Text] [Related]
2. Molecular features underlying differential SHP1/SHP2 binding of immune checkpoint receptors.
Xu X; Masubuchi T; Cai Q; Zhao Y; Hui E
Elife; 2021 Nov; 10():. PubMed ID: 34734802
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory Receptor Trap: A Platform for Discovery of Inhibitory Receptors That Utilize Inositol Lipid and Phosphotyrosine Phosphatase Effectors.
Crute BW; Sheraden R; Ott VL; Harley ITW; Getahun A; Cambier JC
Front Immunol; 2020; 11():592329. PubMed ID: 33193438
[TBL] [Abstract][Full Text] [Related]
4. Molecular interactions of SHP1 and SHP2 in IL-3-signalling.
Wheadon H; Paling NR; Welham MJ
Cell Signal; 2002 Mar; 14(3):219-29. PubMed ID: 11812650
[TBL] [Abstract][Full Text] [Related]
5. SHP1 and SHP2 inhibition enhances the pro-differentiative effect of phorbol esters: an alternative approach against acute myeloid leukemia.
Pérez-Fernández A; López-Ruano G; Prieto-Bermejo R; Ijurko C; Díez-Campelo M; Sánchez-Guijo F; Hernández-Hernández Á
J Exp Clin Cancer Res; 2019 Feb; 38(1):80. PubMed ID: 30764849
[TBL] [Abstract][Full Text] [Related]
6. PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2.
Xu X; Hou B; Fulzele A; Masubuchi T; Zhao Y; Wu Z; Hu Y; Jiang Y; Ma Y; Wang H; Bennett EJ; Fu G; Hui E
J Cell Biol; 2020 Jun; 219(6):. PubMed ID: 32437509
[TBL] [Abstract][Full Text] [Related]
7. T cell-specific constitutive active SHP2 enhances T cell memory formation and reduces T cell activation.
Cammann C; Israel N; Frentzel S; Jeron A; Topfstedt E; Schüler T; Simeoni L; Zenker M; Fehling HJ; Schraven B; Bruder D; Seifert U
Front Immunol; 2022; 13():958616. PubMed ID: 35983034
[TBL] [Abstract][Full Text] [Related]
8. Uncoupling ITIM receptor G6b-B from tyrosine phosphatases Shp1 and Shp2 disrupts murine platelet homeostasis.
Geer MJ; van Geffen JP; Gopalasingam P; Vögtle T; Smith CW; Heising S; Kuijpers MJE; Tullemans BME; Jarvis GE; Eble JA; Jeeves M; Overduin M; Heemskerk JWM; Mazharian A; Senis YA
Blood; 2018 Sep; 132(13):1413-1425. PubMed ID: 29891536
[TBL] [Abstract][Full Text] [Related]
9. Dephosphorylation of ZAP-70 and inhibition of T cell activation by activated SHP1.
Brockdorff J; Williams S; Couture C; Mustelin T
Eur J Immunol; 1999 Aug; 29(8):2539-50. PubMed ID: 10458769
[TBL] [Abstract][Full Text] [Related]
10. Beta-chemokine receptor CCR5 signals through SHP1, SHP2, and Syk.
Ganju RK; Brubaker SA; Chernock RD; Avraham S; Groopman JE
J Biol Chem; 2000 Jun; 275(23):17263-8. PubMed ID: 10747947
[TBL] [Abstract][Full Text] [Related]
11. Themis-associated phosphatase activity controls signaling in T cell development.
Mehta M; Brzostek J; Chen EW; Tung DWH; Chen S; Sankaran S; Yap J; Rybakin V; Gascoigne NRJ
Proc Natl Acad Sci U S A; 2018 Nov; 115(48):E11331-E11340. PubMed ID: 30413615
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine phosphatases Shp1 and Shp2 have unique and opposing roles in oligodendrocyte development.
Kuo E; Park DK; Tzvetanova ID; Leiton CV; Cho BS; Colognato H
J Neurochem; 2010 Apr; 113(1):200-12. PubMed ID: 20132481
[TBL] [Abstract][Full Text] [Related]
13. SHP1 and SHP2 protein-tyrosine phosphatases associate with betac after interleukin-3-induced receptor tyrosine phosphorylation. Identification of potential binding sites and substrates.
Bone H; Dechert U; Jirik F; Schrader JW; Welham MJ
J Biol Chem; 1997 May; 272(22):14470-6. PubMed ID: 9162089
[TBL] [Abstract][Full Text] [Related]
14. Megakaryocyte-specific deletion of the protein-tyrosine phosphatases Shp1 and Shp2 causes abnormal megakaryocyte development, platelet production, and function.
Mazharian A; Mori J; Wang YJ; Heising S; Neel BG; Watson SP; Senis YA
Blood; 2013 May; 121(20):4205-20. PubMed ID: 23509158
[TBL] [Abstract][Full Text] [Related]
15. ITIM-dependent endocytosis of CD33-related Siglecs: role of intracellular domain, tyrosine phosphorylation, and the tyrosine phosphatases, Shp1 and Shp2.
Walter RB; Raden BW; Zeng R; Häusermann P; Bernstein ID; Cooper JA
J Leukoc Biol; 2008 Jan; 83(1):200-11. PubMed ID: 17947393
[TBL] [Abstract][Full Text] [Related]
16. Structural and functional dissection of the cytoplasmic domain of the transmembrane adaptor protein SIT (SHP2-interacting transmembrane adaptor protein).
Pfrepper KI; Marie-Cardine A; Simeoni L; Kuramitsu Y; Leo A; Spicka J; Hilgert I; Scherer J; Schraven B
Eur J Immunol; 2001 Jun; 31(6):1825-36. PubMed ID: 11433379
[TBL] [Abstract][Full Text] [Related]
17. Phase separation ability and phosphatase activity of the SHP1-R360E mutant.
Zhang Q; Kong W; Zhu T; Zhu G; Zhu J; Kong X; Du Y
Biochem Biophys Res Commun; 2022 Apr; 600():150-155. PubMed ID: 35219918
[TBL] [Abstract][Full Text] [Related]
18. Protein tyrosine phosphatase SHP2/PTPN11 mistargeting as a consequence of SH2-domain point mutations associated with Noonan Syndrome and leukemia.
Müller PJ; Rigbolt KT; Paterok D; Piehler J; Vanselow J; Lasonder E; Andersen JS; Schaper F; Sobota RM
J Proteomics; 2013 Jun; 84():132-47. PubMed ID: 23584145
[TBL] [Abstract][Full Text] [Related]
19. SHP2-interacting transmembrane adaptor protein (SIT), a novel disulfide-linked dimer regulating human T cell activation.
Marie-Cardine A; Kirchgessner H; Bruyns E; Shevchenko A; Mann M; Autschbach F; Ratnofsky S; Meuer S; Schraven B
J Exp Med; 1999 Apr; 189(8):1181-94. PubMed ID: 10209036
[TBL] [Abstract][Full Text] [Related]
20. Engineering SHP2 Phosphatase for Optical Control.
Ryan A; Janosko CP; Courtney TM; Deiters A
Biochemistry; 2022 Dec; 61(23):2687-2697. PubMed ID: 36346979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
